← Back to Search

Anti-tumor antibiotic

Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 for Non-Hodgkin's Lymphoma

Phase 1

Waitlist Available

Led By Thomas M Habermann

Research Sponsored by Mayo Clinic

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 2 years

Awards & highlights

Study Summary

This trial is testing a new combination of drugs to treat B-cell non-Hodgkin lymphoma that has come back or is not responding to treatment.

Eligible Conditions

Non-Hodgkin's Lymphoma
Lymphoma

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Maximum tolerated dose (MTD)

Secondary outcome measures

Overall survival

Progression free survival

Tumor response

Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment (AR160)Experimental Treatment3 Interventions

Patients receive nab-paclitaxel/rituximab-coated nanoparticle AR160 IV over 30-60 minutes on days 1, 8, and 15. Cycles repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Nab-paclitaxel/Rituximab-coated Nanoparticle AR160

2019

Completed Phase 1

~10

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor

3,206 Previous Clinical Trials

3,767,074 Total Patients Enrolled

National Cancer Institute (NCI)NIH

13,657 Previous Clinical Trials

40,933,658 Total Patients Enrolled

Thomas M HabermannPrincipal InvestigatorMayo Clinic in Rochester

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any risks associated with Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 treatment?

"As this is an early-phase clinical trial, our team at Power evaluated the safety of Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 as a 1 due to its limited data regarding efficacy and safety."

Answered by AI

Is there an open enrollment period for this trial?

"Affirmative. According to clinicaltrials.gov, the trial is actively recruiting participants; it was posted on April 25th 2019 and last updated July 15th 2022. This particular study requires 18 individuals from a single site."

Answered by AI

What is the total cohort size of this clinical trial?

"Affirmative. According to the clinicaltrials.gov listing, this medical trial is actively seeking participants; it was first released on April 25th 2019 and later updated on July 15th 2022. The study requires 18 individuals from one location."

Answered by AI

What diseases can Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 help patients manage?

"Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 is a commonly prescribed treatment for metastatic bladder cancer, as well as acquired immunodeficiency syndrome, dlbcl and advanced thymoma."

Answered by AI

Has Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 been tested in any previous research studies?

"Presently, there are 1,235 active trials for Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 with 319 of them in the third phase. Shanghai hosts a majority of these studies but 59,961 medical sites worldwide are running clinical testing on this medication."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial

2019. "Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03003546.